Abstract:CONTEXT: The use of systemic estrogens for the treatment of menopausal symptoms has declined by approximately 80% following the initial publication of the Women's Health Initiative in 2002. Current attention focuses on vaginal estrogen as a local therapeutic means to achieve control of symptoms due to vulvovaginal atrophy without increasing plasma estradiol levels. A key issue is whether or not vaginally administered estrogens are absorbed and produce systemic effects.EVIDENCE ACQUISITION: Medline and PubMed were searched for relevant English-language articles using pertinent key words. The bibliographies of the pertinent articles were then read to identify further relevant articles.EVIDENCE SYNTHESIS: Several confounding factors influenced the data analysis including: (1) estradiol assay sensitivity and specificity; (2) acute versus chronic absorption; (3) delivery systems, doses, timing, and formulation; and (4) effect of atrophic versus mature vaginal mucosa on absorption. Each preparation was associated with acute estradiol absorption with peaks at approximately 8 h and return to baseline at 12 h. Low-dose vaginal estrogen, arbitrarily defined as the 7.5-μg vaginal ring and 10-μg tablet, increased plasma estradiol levels during chronic administration but not above the normal range of ≤ 20 pg/ml. Surprisingly, these increments were associated with systemic effects to lower plasma levels of low density lipoprotein cholesterol and bone resorption rates. Intermediate doses (i.e. 25 μg estradiol or 0.3 mg conjugated equine estrogen) resulted in plasma estradiol levels approaching or exceeding 20 pg/ml. The higher doses (50-2000 μg estradiol or 0.625-2.5 mg conjugated equine estrogen) resulted in premenopausal levels of estrogen.CONCLUSIONS: Low-dose vaginal estrogen appears to be an effective strategy for managing women whose symptoms result from vulvovaginal atrophy. These regimens limit but do not completely eliminate systemic absorption. Low-doses regimens should be preferred clinically to intermediate- or high-dose methods.

Vaginal ring delivery of hormone replacement therapy--a review

Low-dose intravaginal estradiol delivery using a Silastic vaginal ring for estrogen replacement therapy in postmenopausal women: a review

Oestradiol-releasing vaginal ring for treatment of postmenopausal urogenital atrophy

Estrogens and the urogenital tract. Studies on steroid hormone receptors and a clinical study on a new estradiol-releasing vaginal ring

[Vaginal contraception: new form of administration of hormonal contraception]

Optimising delivery systems for HRT

Safety and acceptability of intravaginal rings releasing estradiol and progesterone

Ultra-low-dose vaginal estrogen tablets for the treatment of postmenopausal vaginal atrophy

Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels

Treatment of postmenopausal vaginal atrophy with 10-μg estradiol vaginal tablets

Ethinylestradiol + etonogestrel contraceptive vaginal ring: new drug. Possibly useful in some situations

Fabrication of a Reservoir Ring for Sustained and Prolonged Release of Levonorgestrel for Vaginal Administration

Pharmacotherapy for the treatment of vaginal atrophy

Hormone replacement therapy: the benefits in tailoring the regimen and dose

Vaginal Hormone Therapy for Conditions of the Lower Urinary Tract

Hormone replacement therapy in the menopause

A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery

Effectiveness of hormones in postmenopausal pelvic floor dysfunction—International Urogynecological Association research and development—committee opinion

THE INVESTIGATION OF PHARMACOLOGICAL PROPERTIES OF VAGINAL GEL WITH RESVERATROL AND HYALURONIC ACID IN CONDITIONS OF EXPERIMENTAL HYPOESTROGENIC STATE IN RATS

Vaginal oestrogen is a treatment on the rise, but is it safe?

Local Hormonal Therapy for Genitourinary Menopausal Syndrome